522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)

BACKGROUND: Recurrence of Clostridioides difficile infection (rCDI) is common - up to 35% of patients may recur. RBX2660 is a microbiota restoration therapy to reduce rCDI. Here we report 8 weeks HRQL results using the Clostridioides difficile Health-related Quality-of-Life Questionnaire (Cdiff32),...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuerstadt, Paul, Dubberke, Erik R, Guo, Amy, Harvey, Adam, Yang, Min, García-Horton, Viviana, Fillbrunn, Mirko, Tillotson, Glenn S, Bancke, Lindy, Garey, Kevin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751853/
http://dx.doi.org/10.1093/ofid/ofac492.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751853/
http://dx.doi.org/10.1093/ofid/ofac492.577

Ejemplares similares